Sentara Infusion Services recalls NALBUPHINE (a) 1.5MG IN 1.5ML NS, (b) 2.5MG IN 2.5ML NS, SYRINGE, pain, Rx Only, Sentara Home Infusion Pharmacy Service…
- Recall date
- December 27, 2022
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Recall number
- D-0311-2023
- FDA classification
- Class II
- Brand / firm
- Sentara Infusion Services
- Sold / distributed
- Dispensed to Patients Nationwide.
Why it was recalled
Lack of sterility assurance
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
NALBUPHINE (a) 1.5MG IN 1.5ML NS, (b) 2.5MG IN 2.5ML NS, SYRINGE, pain, Rx Only, Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320
Get recall alerts
Free email alert whenever Sentara Infusion Services has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Sentara Infusion Services